Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.
复制标题
DOI：
10.1186/s13046-022-02293-6
复制
发表时间：
2022-03-22
期刊：
影响因子：
--
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Ashrafizadeh M;Paskeh MDA;Mirzaei S;Gholami MH;Zarrabi A;Hashemi F;Hushmandi K;Hashemi M;Nabavi N;Crea F;Ren J;Klionsky DJ;Kumar AP;Wang Y
Prostate cancer is a leading cause of death worldwide and new estimates revealed prostate cancer as the leading cause of death in men in 2021. Therefore, new strategies are pertinent in the treatment of this malignant disease. Macroautophagy/autophagy is a “self-degradation” mechanism capable of facilitating the turnover of long-lived and toxic macromolecules and organelles. Recently, attention has been drawn towards the role of autophagy in cancer and how its modulation provides effective cancer therapy. In the present review, we provide a mechanistic discussion of autophagy in prostate cancer. Autophagy can promote/inhibit proliferation and survival of prostate cancer cells. Besides, metastasis of prostate cancer cells is affected (via induction and inhibition) by autophagy. Autophagy can affect the response of prostate cancer cells to therapy such as chemotherapy and radiotherapy, given the close association between autophagy and apoptosis. Increasing evidence has demonstrated that upstream mediators such as AMPK, non-coding RNAs, KLF5, MTOR and others regulate autophagy in prostate cancer. Anti-tumor compounds, for instance phytochemicals, dually inhibit or induce autophagy in prostate cancer therapy. For improving prostate cancer therapy, nanotherapeutics such as chitosan nanoparticles have been developed. With respect to the context-dependent role of autophagy in prostate cancer, genetic tools such as siRNA and CRISPR-Cas9 can be utilized for targeting autophagic genes. Finally, these findings can be translated into preclinical and clinical studies to improve survival and prognosis of prostate cancer patients. • Prostate cancer is among the leading causes of death in men where targeting autophagy is of importance in treatment; • Autophagy governs proliferation and metastasis capacity of prostate cancer cells; • Autophagy modulation is of interest in improving the therapeutic response of prostate cancer cells; • Molecular pathways, especially involving non-coding RNAs, regulate autophagy in prostate cancer; • Autophagy possesses both diagnostic and prognostic roles in prostate cancer, with promises for clinical application.
登录
查看更多内容
影响因子：
5.2
作者：
Archer M;Dogra N;Kyprianou N
通讯作者：
Kyprianou N
影响因子：
6.2
作者：
Aguirre-Hernandez, Carmen;Maya-Pineda, Hector;Hallden, Gunnel
通讯作者：
Hallden, Gunnel
影响因子：
--
作者：
Akhtar N;Syed DN;Khan MI;Adhami VM;Mirza B;Mukhtar H
通讯作者：
Mukhtar H
影响因子：
4.2
作者：
Arisan, Elif Damla;Rencuzogullari, Ozge;Uysal-Onganer, Pinar
通讯作者：
Uysal-Onganer, Pinar
影响因子：
6.1
作者：
Ashrafizadeh, Milad;Zarrabi, Ali;Najafi, Masoud
通讯作者：
Najafi, Masoud